Nicki Panoskaltsis

Nicki is a Physician-scientist with a niche interest in translational interdisciplinary
research and personalised therapeutics, focused in Haemato-Oncology. She completed her MD at the University of Toronto (Canada), clinical training and American Board Certification in Internal Medicine, Haematology and Bone Marrow Transplantation at the University of Rochester (USA) and a PhD in Immunology at Imperial College London (UK) where she stayed on as faculty until 2018. She then moved her programme to the Winship Cancer Institute at Emory University, an NCI-Designated
Comprehensive Cancer Centre, where she was Senior Faculty within the Department of Hematology & Medical Oncology, an Attending Physician and Clinical Researcher in the Leukemia Program, and Program Faculty in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Institute of Technology and Emory University. She is now Professor and Chair of Personalised Therapeutics at Trinity College Dublin. She co-leads an interdisciplinary research lab with unique expertise in organoid cultures, cell bioprocessing and in silico modelling techniques. Professor Panoskaltsis has an
international reputation in cytokine release syndrome and defensive clinical trial design based on her seminal research and successful handling of the aftermath of the TGN1412 CD28 super-agonist immunotherapy first-in-human trial in 2006 (London UK) which resulted in changes to the conduct of first-in-human trials for novel higher-risk therapeutics, enabling safe implementation of immunotherapy on an international scale, and for which she was made a Fellow of the Royal College of Physicians (London).